The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in-breast failure in patients with early-stage breast cancer treated with breast-conserving therapy

Cancer

Volumn 109, Issue 7, 2007, Pages 1264-1272

  Vicini, Frank A ^a   Antonucci, J Vito ^a   Goldstein, Neal ^a   Wallace, Michelle ^a   Kestin, Larry ^a   Krauss, Daniel ^a   Kunzmann, Jonathan ^a   Gilbert, Samuel ^a   Schell, Scott ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Breast conserving therapy; Local recurrence; Loss of heterozygosity; Lumpectomy; Radiation therapy

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BRACHYTHERAPY; BREAST CANCER; BREAST TUMOR; CANCER CLASSIFICATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLONAL VARIATION; CONSERVATIVE TREATMENT; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; HETEROZYGOSITY LOSS; HUMAN; INVASIVE CARCINOMA; METASTASIS; MOLECULAR BIOLOGY; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; TREATMENT FAILURE; TUMOR RECURRENCE;

BREAST NEOPLASMS; CLONE CELLS; DIAGNOSIS, DIFFERENTIAL; DNA, NEOPLASM; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; MICROSATELLITE REPEATS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS;

EID: 33947532436     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22529     Document Type: Article

References (44)

1. Haffty BG, Reiss M, Beinfield M, Fischer D, Ward B, McKhann C. Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. J Clin Oncol. 1996;14:52-57.
2. Recht A, Silen W, Schnitt SI, et al. Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1988;15:255-261.
3. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science. 1997;278:1054-1059.
4. Lasko D, Cavenee W, Nordenskjold M. Loss of constitutional heterozygosity in human cancer. Annu Rev Genet. 1991;25:281-314.
5. Bianchi AB, Navone NM, Conti CJ. Detection of loss of heterozygosity in formalin-fixed paraffin-embedded tumor specimens by the polymerase chain reaction. Am J Pathol. 1991;138:279-284.
6. Wang Y, Hung SC, Linn JP, et al. Microsatellite-based cancer detection using capillary array electrophoresis and energy-transfer fluorescent primers. Electrophoresis. 1997; 18:1742-1749.
7. Mead LJ, Gillespie MT, Hung JY, et al. Frequent loss of heterozygosity in early non-small cell lung cancers at chromosome 9p21 proximal to the CDKN2a gene. Int J Cancer. 1997;71:213-217.
8. Leong PP, Rezai B, Koch WM, et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst. 1998;90:972-977.
9. Kollias J, Man S, Marafie M, et al. Loss of heterozygosity in bilateral breast cancer. Breast Cancer Res Treat. 2000;64: 241-251.
10. Kung FY, Tse GM, Lo KW, Law BK, Chang AR, Chen MH. Metachronous bilateral mammary metaplastic and infiltrating duct carcinomas: a molecular study for clonality. Hum Pathol. 2002;33:677-679.
11. Lininger RA, Fujii H, Man YG, Gabrielson E, Tavassoli FA. Comparison of loss heterozygosity in primary and recurrent ductal carcinoma in situ of the breast. Mod Pathol. 1998;11:1151-1159.
12. Regitnig P, Moser R, Thalhammer M, et al. Microsatellite analysis of breast carcinoma and corresponding local recurrences. J Pathol. 2002;198:190-197.
13. Regitnig P, Ploner F, Maderbacher M, Lax SF. Bilateral carcinomas of the breast with local recurrence: analysis of genetic relationship of the tumors. Mod Pathol. 2004;17: 597-602.
14. Tse GM, Kung FY, Chan AB, Law BK, Chang AR, Lo KW. Clonal analysis of bilateral mammary carcinomas by clinical evaluation and partial allelotyping. Am J Clin Pathol. 2003;120:168-174.
15. Schlechter BL, Yang Q, Larson PS, et al. Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. J Clin Oncol. 2004;22: 1830-1838.
16. Hampl M, Hampl JA, Reiss G, Schackert G, Saeger HD, Schackert HK. Loss of heterozygosity accumulation in primary breast carcinomas and additionally in corresponding distant metastases is associated with poor outcome. Clin Cancer Res. 1999;5:1417-1425.
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
18. Vicini FA, Goldstein NS, Pass H, Kestin LL. Use of pathologic factors to assist in establishing adequacy of excision before radiotherapy in patients treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2004; 60:86-94.
19. Vicini FA, Kestin L, Chen P, Benitez P, Goldstein NS, Martinez A. Limited-field radiation therapy in the management of early-stage breast cancer. J Natl Cancer Inst. 2003;95: 1205-1210.
20. Vicini FA, Beitsch PD, Quiet CA, et al. First analysis of patient demographics, technical reproducibility, cosmesis, and early toxicity: results of the American Society of Breast Surgeons MammoSite breast brachytherapy trial. Cancer. 2005;104:1138-1148.
21. Goldstein NS, Vicini FA, Hunter S, et al. Molecular clonality determination of ipsilateral recurrence of invasive breast carcinomas after breast-conserving therapy: comparison with clinical and biologic factors. Am J Clin Pathol. 2005;123:679-689.
22. Goldstein NS, Vicini FA, Hunter S, Odish E, Forbes S, Kestin LL. Molecular clonality relationships in initial carcinomas, ipsilateral breast failures, and distant metastases in patients treated with breast-conserving therapy: evidence suggesting that some distant metastases are derived from ipsilateral breast failures and that metastases can metastasize. Am J Clin Pathol. 2005;124:49-57.
23. Sieben NL, Kolkman-Uljee SM, Flanagan AM, et al. Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumors. Am J Pathol. 2003;162: 1095-1101.
24. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat. 1958;53:457-481.
25. Huang E, Buchholz TA, Meric F, et al. Classifying local disease recurrences after breast conservation therapy based on location and histology. Cancer. 2002;95:2059-2067.
26. Krauss DJ, Kestin LL, Mitchell C, Martinez AA, Vicini FA. Changes in temporal patterns of local failure after breast-conserving therapy and their prognostic implications. Int J Radiat Oncol Biol Phys. 2004;60:731-740.
27. Fowble B. Ipsilateral breast tumor recurrence following breast-conserving surgery for early-stage invasive cancer. Acta Oncol. 1999;38(Suppl 13):9-17.
28. Doyle T, Schultz DJ, Peters C, Harris E, Solin LJ. Long-term results of local recurrence after breast conservation treatment for invasive breast cancer. Int J Radiat Oncol Biol Phys. 2001;51:74-80.
29. Haffty BG, Fischer D, Beinfield M, McKhann C. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys. 1991;21:293-298.
30. Fowble B, Solin LJ, Schultz DJ, Rubenstein J, Goodman RL. Breast recurrence following conservative surgery and radiation: patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment. Int J Radiat Oncol Biol Phys. 1990;19: 833-842.
31. DiPaola RS, Orel SG, Fowble BL. Ipsilateral breast tumor recurrence following conservative surgery and radiation therapy. Oncology (Huntington). 1994;8:59-68.
32. Hameed O, Pfeifer JD. Classifying "recurrent" breast cancer: lost heterozygosity found. Am J Clin Pathol. 2005;123: 641-643.
33. Nakayama T, Taback B, Turner R, Morton DL, Hoon DS. Molecular clonality of in-transit melanoma metastasis. Am J Pathol. 2001;158:1371-1378.
34. Huang J, Behrens C, Wistuba I, Gazdar AF, Jagirdar J. Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis. Ann Diagn Pathol. 2001;5:321-329.
35. Altimari A, Gruppioni E, Fiorentino M, et al. Genomic allelotyping for distinction of recurrent and de novo hepatocellular carcinoma after orthotopic liver transplantation. Diagn Mol Pathol. 2005;14:34-38.
36. Smith TE, Lee D, Turner BC, Carter D, Haffty BG. True recurrence vs new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys. 2000;48:1281-1289.
37. Li Z, Moore DH, Meng ZH, Ljung BM, Gray JW, Dairkee SH. Increased risk of local recurrence is associated with allelic loss in normal lobules of breast cancer patients. Cancer Res. 2002;62:1000-1003.
38. Lakhani SR, Chaggar R, Davies S, et al. Genetic alterations in 'normal' luminal and myoepithelial cells of the breast. J Pathol. 1999;189:496-503.
39. Euhus DM, Cler L, Shivapurkar N, et al. Loss of heterozygosity in benign breast epithelium in relation to breast cancer risk. J Natl Cancer Inst. 2002;94:858-860.
40. Forsti A, Louhelainen J, Soderberg M, Wijkstrom H, Hemminki K. Loss of heterozygosity in tumour-adjacent normal tissue of breast and bladder cancer. Eur J Cancer. 2001;37: 1372-1380.
41. Lichy JH, Dalbegue F, Zavar M, et al. Genetic heterogeneity in ductal carcinoma of the breast. Lab Invest. 2000;80:291-301.
42. Jones C, Merrett S, Thomas VA, Barker TH, Lakhani SR. Comparative genomic hybridization analysis of bilateral hyperplasia of usual type of the breast. J Pathol. 2003;199: 152-156.
43. Going JJ. Stages on the way to breast cancer. J Pathol. 2003;199:1-3.
44. Boecker W, Buerger H, Schmitz K, et al. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. J Pathol. 2001;195:415-421.